Global E-Cigarette Liquid Market to Reach $37 Billion by 2028

Aug.23.2022
Global E-Cigarette Liquid Market to Reach $37 Billion by 2028
The global e-cigarette liquid market is projected to reach $3.7 billion by 2028, driven by increasing health awareness and demand for safer smoking alternatives.

Market.US has released a research report stating that the global e-cigarette e-liquid market was valued at $1.7 billion in 2020 and is expected to reach $3.7 billion by 2028. The market is projected to grow at a CAGR of 12.8% from 2021 to 2028.


An increasing number of people are turning to safer smoking alternatives as awareness regarding health issues continues to grow. Electronic cigarettes are known to contain lower levels of toxic substances, and offer various flavors such as tobacco, mint, fruit, and nut. This is expected to fuel the consumption of e-cigarette oil.


Electronic cigarettes, unlike traditional tobacco cigarettes, do not contain tobacco and do not produce tar or carbon monoxide. This makes them a safer alternative to smoking. As people become more aware of the harmful effects of smoking on their health, they are more likely to quit, leading to a positive impact on the global sales of electronic cigarettes. This is one of the many reasons why the electronic cigarette industry is thriving.


Global E-liquid Market: Driving Factors


Electronic cigarette liquid is often used as a substitute for traditional tobacco. E-cigarette liquid can be infused with many flavors, providing a fresh and enhanced taste.


Electronic cigarettes are different from traditional cigarettes in that they allow you to inhale fewer toxic substances, reducing the risk of lung disease. These factors are expected to drive growth in the global liquid market. The use of e-liquid in electronic cigarettes helps reduce environmental damage, which is why manufacturers are focusing on liquid e-cigarettes, which are becoming increasingly popular. Green e-cigarettes are an obvious trend, eliminating the environmental burden associated with handling large amounts of cigarette butts.


Furthermore, electronic cigarettes reduce the issue of deforestation and the environmental degradation caused by tobacco production. Compared to traditional smoking, electronic cigarettes provide many advantages to smokers, helping them to reduce their intake of tar and nicotine and leading many to partially or completely quit smoking. These health benefits are driving demand for liquid nicotine in the electronic cigarette market. However, government regulation of e-cigarettes as tobacco products may hinder the future growth of the global e-liquid market.


The main trend in the market: Nicotine salts.


E-cigarettes are considered safer because they do not burn tobacco or produce tar or carbon monoxide. As knowledge about e-cigarettes increases, sales have also been on the rise. This is one of the main factors driving the growth of the e-cigarette oil market. Health authorities and organizations around the world are taking measures to reduce tobacco use, including indoor smoking bans and high taxes. This has encouraged people to use e-cigarettes as a means to quit smoking and has driven market growth.


Leading manufacturers are utilizing social media to promote their products, providing customized flavors, and implementing innovative marketing strategies. Online distribution channels are also being used for e-cigarette accessories and kits. With both open and closed systems becoming increasingly popular, there is an expected increase in global demand. The research report addresses the following questions:


Who are the main players in the electronic e-liquid market? What are the main driving factors for the growth of the electronic e-liquid market? Based on what types of categories is the global electronic e-liquid market classified? What is the expected market size and growth rate of the electronic e-liquid market in the future? In 2021, which distribution channels dominate the electronic e-liquid industry? What criteria are used when selecting companies?


Click to view a sample research report.


Statement


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of the article's content. The compilation of this article is only intended for industry communication and research.


Due to the limitations of the translation ability, the translated article may not accurately reflect the original text. Please refer to the original text for accuracy.


2FIRSTS is fully aligned with the Chinese government on any domestic, Hong Kong-Macau-Taiwan-related, and foreign related statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Alimentation Couche-Tard said U.S. same-store sales in its “other nicotine products” category grew at a double-digit rate in the first quarter of fiscal 2027, led by nicotine pouches, while overall U.S. same-store merchandise revenues increased 1.7%. The company also said its Canadian nicotine business continued to face regulatory pressure and illicit-market headwinds. The U.S. performance coincides with Couche-Tard's participation in efforts to reopen Canadian convenience-store access to authorized nicotine pouches, though the company has not established a direct causal link between the two.
Sep.14
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania's Act 57 vape directory regime will reach the end of its 120-day inventory transition period on Oct. 19. Nicotine-containing e-cigarettes intended for retail sale in the state that are not listed on the Attorney General's ENDS directory will then be barred from retail sale and treated as contraband subject to seizure, forfeiture and destruction. Manufacturers face annual product certification, brand- and style-based fees and a minimum $50,000 surety bond, while retailers and wholesalers must source through licensed channels and monitor the directory.
Regulations
Oct.08
JTI Proposes 25-Cent Irish Cigarette Tax Increase, Says It Could Raise €45 Million
JTI Proposes 25-Cent Irish Cigarette Tax Increase, Says It Could Raise €45 Million
Japan Tobacco International's Irish business has proposed a €0.25 tax increase on a pack of 20 cigarettes in its pre-Budget 2027 submission, below the €0.50-or-more increases typically imposed in recent Irish budgets. JTI says the proposal could generate around €45 million in additional Exchequer revenue while limiting further movement toward illicit and non-Irish-tax-paid tobacco. Revenue's existing estimate for a comparable €0.25 increase, including pro-rata rises on other tobacco products, is about €18 million for a full year.
JTI
Sep.18 by 2Firsts Perspectives